Assignee
CEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
AT·7 granted patents·13 pending applications·9 citations·filing 2014–2022
Top patents by PatentIndex Score
20 records- 0173US10934636B2Methods for studying nucleic acidsCEMM—FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2016·Granted Mar 2, 2021·3 cites·31 claims
- 0273US9999621B2Medical use of artemisinin compounds and gephyrin agonistsCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2015·Granted Jun 19, 2018·2 cites·21 claims
- 0371US10702518B2TAF1 inhibitors for the therapy of cancerCEMM—FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2017·Granted Jul 7, 2020·2 cites·14 claims
- 0471US2022251666A1Mutant calreticulin for the diagnosis of myeloid malignanciesCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2022·Application pending·0 cites
- 0566US11274350B2Mutant calreticulin for the diagnosis of myeloid malignanciesCEMM—FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2019·Granted Mar 15, 2022·0 cites·22 claims
- 0666US10344335B2Mutant calreticulin for the diagnosis of myeloid malignanciesCEMM—FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2014·Granted Jul 9, 2019·1 cites·22 claims
- 0759US11486876B2Monolayer of PBMCs or bone-marrow cells and uses thereofCEMM—FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2015·Granted Nov 1, 2022·1 cites·14 claims
- 0853US2023241226A1Compounds for targeted degradation of carrier proteins and uses thereofCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2020·Application pending·0 cites
- 0953US2018251852A1Mutant calreticulin for the diagnosis of myeloid malignanciesCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2018·Application pending·0 cites
- 1052US2024270749A11,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic useCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2022·Application pending·0 cites
- 1152US2024141445A1Novel method for pooled intron tagging for real time drug screeningCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2020·Application pending·0 cites
- 1251US2024101692A1Anti-april antibodies and uses thereofCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2021·Application pending·0 cites
- 1350US2024132485A1Heterocyclic cullin ring ubiquitin ligase compounds and uses thereofCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2021·Application pending·0 cites
- 1447US2020171056A1Sulfonylurea compounds in the treatment of disease associated with uv-induced damageCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2018·Application pending·0 cites
- 1543US10864190B2Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancerCEMM—FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2016·Granted Dec 15, 2020·0 cites·5 claims
- 1642US2024287596A1Method for sequencing rna oligonucleotidesCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2020·Application pending·0 cites
- 1736US2020064348A1Methods for determining interaction between biological cellsCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2018·Application pending·0 cites
- 1835US2021181183A1Methods for determining selectivity of test compoundsCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2018·Application pending·0 cites
- 1931US2019262355A1Combination of a brd4 inhibitor and an antifolate for the therapy of cancerCEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2017·Application pending·0 cites
- 2031US2017269092A1Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignanciesCEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →